Drug

Ezogabine

Established medicine

ClassKCNQ (Kv7) potassium channel openerResearchOngoing clinical research

Also known as EZG, Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester+4 more

EZG, Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, Potiga, RTG, Retigabina, Retigabine.

RxNorm1112990 ChEMBLCHEMBL41355 ATCN03AX21UNII12G01I6BBU

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Developing Neuronal KCNQ Channel Modulators for Mood Disorders

Clinical trial2020-10-23Results posted · ClinicalTrials.gov

A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis

Clinical trial2019-08-28Results posted · ClinicalTrials.gov

A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder

Clinical trial2019-04-16Results posted · ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia

Clinical trial2018-05-08Results posted · ClinicalTrials.gov

Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures

Clinical trial2017-04-21Results posted · ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures

Clinical trial2016-12-08Results posted · ClinicalTrials.gov

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

Clinical trial2014-01-01Completed · ClinicalTrials.gov

An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Clinical trial2012-10-18Withdrawn · ClinicalTrials.gov

Relative Bioavailability of Different n-3 Fatty Acid Formulations in Humans

Clinical trial2011-07-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ezogabine

Aliases & brands

EZGEthyl 2-amino-4-((p-fluorobenzyl)amino)carbanilateN-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl esterN-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl esterPotigaRTGRetigabinaRetigabine

RxNorm CUI

1112990

ChEMBL ID

CHEMBL41355

ATC codes

N03AX21

UNII

12G01I6BBU

Primary mechanism

KCNQ (Kv7) potassium channel opener